Reynolds files lawsuit in California over tobacco products

May.15.2023
Reynolds files lawsuit in California over tobacco products
Reynolds Tobacco files lawsuit in California to defend its non-menthol tobacco products against flavor ban allegations.

On May 12th, Convenience Store News reported that Reynolds Tobacco filed a lawsuit against officials, including California Attorney General Robert Bonta, in response to several notices issued by Bonta alleging that Reynolds Tobacco and certain brands under the Empire Tobacco umbrella "presumptively" marketed flavored tobacco products.


Renault believes that the new product complies with California law.


Tobacco company Reynolds American Inc. has announced that it is taking action to maintain the availability of its legal "non-menthol" tobacco products in the California market. The company filed a lawsuit in California court seeking declaratory and injunctive relief, including the overturning of warning notifications from California authorities.


Renault Tobacco has expressed its support for its new products and believes that they comply with California's laws and can continue to be sold. Renault stated that it had followed all applicable pre-market regulatory requirements before launching these products for sale.


The company's statement stated:


The new Camel and Newport brand tobacco products do not have any discernible flavor or scent other than tobacco, and explicitly state that they are non-menthol on the market.


Renault Tobacco believes that the notification from the California Attorney General's office failed to acknowledge the fact that the newly launched product is prominently labeled as non-menthol and is being sold in the market.


California Attorney General Accuses Reno of Violating Flavoring Ban with New Product.


Previously, California's Attorney General, Xavier Becerra, issued warning letters to Reynolds and Imperial Tobacco stating that California law enforcement officials discovered through a review of cigarette packaging and promotional materials that several products were "presumed to be flavored products in violation of California's flavor ban.


The California Attorney General's office has identified seven products from R.J. Reynolds Tobacco, including Camel Crush Oasis Silver, Camel Crush Oasis Blue, Camel Crush Oasis Green, Camel Crisp, Newport EXP Non-Menthol Mix, Newport EXP Non-Menthol Max, and Newport Non-Menthol Green, as "flavored" tobacco products. Similarly, two products from Imperial Tobacco, Kool Non-Menthol and Kool Blue Non-Menthol, have been identified as "flavored" tobacco products as well.


These two companies are required to respond to these notices before June 23rd.


The Battle Against Flavored Tobacco in California.


On November 8th, 2022, California approved Proposition 31 with approximately 62.3% of voters in favor and 37.7% against. Proposition 31 upholds the state law banning the sale of flavored tobacco, including menthol.


The vote result was immediately met with opposition from tobacco companies, with companies such as Renault suing the California government in the US Supreme Court. However, on December 12th, the US Supreme Court rejected the plea of multiple tobacco companies to halt the implementation of the state's ban on the sale of flavored tobacco products.


According to Renault, the company has repeatedly urged law enforcement officials in California to take action against illegal and unregulated disposable electronic cigarettes that are being smuggled into the state from unknown sources through its ports.


Reference:


Reynolds has initiated legal action in California with the aim of safeguarding the legal sale and distribution of its tobacco products.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

2Firsts On-Site | PMI Brings IQOS, ZYN, VEEV and Marlboro Together at Its “Boulevard” at InterTabac 2026
2Firsts On-Site | PMI Brings IQOS, ZYN, VEEV and Marlboro Together at Its “Boulevard” at InterTabac 2026
At InterTabac 2026 in Dortmund, PMI is presenting multiple brands and products along “The PMI Boulevard,” including IQOS, ZYN, VEEV and Marlboro. On-site images captured by 2Firsts show dedicated spaces including the IQOS Boutique, ZYN Café, PMI Gallery and Marlboro Office
Market
Sep.16 by 2Firsts Perspectives
FDA Grants PMTA Authorization to 11 ZYN ULTRA Nicotine Pouches, Bringing Total Authorized Pouches to 43
FDA Grants PMTA Authorization to 11 ZYN ULTRA Nicotine Pouches, Bringing Total Authorized Pouches to 43
The U.S. Food and Drug Administration authorized 11 ZYN ULTRA nicotine pouch products made by Swedish Match USA through the premarket tobacco product application pathway on August 21, 2026. Ten of the authorized products have a labeled nicotine content of 9 mg, while ZYN ULTRA Smooth was authorized at 11 mg. The reviews were conducted through FDA’s nicotine pouch PMTA pilot program. FDA has now authorized 43 nicotine pouch products, including 23 through the pilot.
Aug.24
FRE and ALP Push Modern Oral to 48% of Q2 Sales as Turning Point Brands Changes CEO and Lowers Profit-Guidance Ceiling
FRE and ALP Push Modern Oral to 48% of Q2 Sales as Turning Point Brands Changes CEO and Lowers Profit-Guidance Ceiling
Turning Point Brands said Executive Chairman David E. Glazek will become CEO on October 1, replacing Graham Purdy, who is stepping down for personal reasons. The company narrowed its 2026 adjusted EBITDA outlook to $70 million-$80 million from $70 million-$90 million while maintaining Modern Oral gross sales guidance of $330 million-$350 million and net sales guidance of $260 million-$270 million. In the second quarter, Modern Oral net sales rose 128% to $68.4 million and accounted for 48% of company-wide net sales. Adjusted EBITDA fell 50% year over year. TPB shares closed about 10% lower on September 21.
Market
Sep.22 by 2Firsts Perspectives
JAMA Issues First U.S. Clinical Guidance on Vaping for Smoking Cessation, Urging Complete Switch From Cigarettes
JAMA Issues First U.S. Clinical Guidance on Vaping for Smoking Cessation, Urging Complete Switch From Cigarettes
JAMA has published a Special Communication offering systematic recommendations for U.S.-based clinicians on the use of nicotine e-cigarettes in adult smoking cessation. Developed by the Harm Reduction Workgroup of the Society for Research on Nicotine and Tobacco’s Treatment Research Network, the paper recommends including e-cigarettes alongside FDA-approved cessation medications in risk-benefit discussions. It cites high-certainty evidence that nicotine e-cigarettes achieve higher quit rates than nicotine replacement therapy and evidence suggesting efficacy comparable to highly effective medications such as varenicline and cytisine. For adults who choose vaping to quit, the authors recommend FDA-authorized products, sufficient nicotine delivery and a rapid, complete transition away from cigarettes rather than prolonged dual use.
Aug.13
NATO Executive Director David Spross Sees U.S. Vape Regulation Improving, Calls for More PMTA Authorizations and Warns of 2027 State Tax Pressure
NATO Executive Director David Spross Sees U.S. Vape Regulation Improving, Calls for More PMTA Authorizations and Warns of 2027 State Tax Pressure
The National Association of Tobacco Outlets is calling for more FDA marketing authorizations, greater transparency in the PMTA process and continued enforcement against unauthorized e-cigarettes, even as its executive director, David Spross, points to recent regulatory developments as signs of progress. At the state level, excise taxes, flavor restrictions and vapor product directories remain major issues for tobacco retailers. By August 2026, 17 states had enacted laws establishing state-managed e-cigarette directories or similar systems.
Innovation
Sep.29 by 2Firsts Perspectives
FDA Unifies Tobacco Registration and Product Listing Form Across Product Categories
FDA Unifies Tobacco Registration and Product Listing Form Across Product Categories
The U.S. FDA has consolidated two tobacco establishment registration and product listing forms into a redesigned Form FDA 3741 covering all regulated product categories, including e-cigarettes, heated tobacco products and nicotine pouches. The current requirements remain limited to domestic establishments. Separately, the FDA has proposed extending registration and product listing requirements to foreign manufacturers, signaling greater regulatory attention to manufacturing entities and product-level information across the tobacco and nicotine supply chain.
FDA
Sep.30